Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PDE9A | O76083 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 2/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903271 | 0.88 | HRH4 (0.39) | TSHRPDE9APRMT5ADORA2AADORA1 | |
| SCHEMBL4904524 | 0.76 | RAB9A (0.48) | PDE9A | |
| SCHEMBL4886762 | 0.73 | TSHR (0.43) | TSHRSLC6A4HCAR2 | |
| SCHEMBL4902044 | 0.71 | CXCR2 (0.38) | TSHRPDE9APRMT5ADORA2AADORA1 | |
| SCHEMBL4902965 | 0.69 | TSHR (0.38) | TSHRADORA2AADORA1CCR2SOAT1 | |
| SCHEMBL15555557 | 0.65 | ALDH1A1 (0.49) | TSHRHRH4HRH3HCAR2 | |
| SCHEMBL5311581 | 0.65 | TSHR (1.00) | TSHRSLC6A2SLC6A3 | |
| SCHEMBL27380 | 0.65 | TSHR (1.00) | TSHRSLC6A2SLC6A3 | |
| Benzene SCHEMBL27997624 | 0.65 | TSHR (1.00) | TSHRSLC6A2SLC6A3 | |
| SCHEMBL13638355 | 0.63 | TSHR (0.54) | TSHRHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | PFIZER INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1740550-A1 | SULPHUR-LINKED IMIDAZOLE COMPOUNDS FOR THE TREAMENT OF HIV | Pfizer Limited (GB) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005100322-A1 | SULPHUR-LINKED IMIDAZOLE COMPOUNDS FOR THE TREAMENT OF HIV | PFIZER LIMITED (GB) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | SPR, TPMT, IMPDH1 | TSHR 3874/4885PDE9A 4771/4885PRMT5 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.